Ceribell, Inc. ( (CBLL) ) has released its Q4 earnings. Here is a breakdown of the information Ceribell, Inc. presented to its investors.
Ceribell, Inc. is a medical technology company specializing in the development of innovative solutions for diagnosing and managing serious neurological conditions, with a focus on point-of-care electroencephalography (EEG) systems. The company is known for its Ceribell System, which is designed to provide rapid diagnosis and continuous monitoring in acute care settings.
In its latest earnings report, Ceribell, Inc. announced significant financial growth for the fourth quarter and full year of 2024. The company reported a 41% increase in revenue for the fourth quarter, reaching $18.5 million, and a 45% increase for the full year, totaling $65.4 million. These results reflect the company’s successful expansion and adoption of its Ceribell System across new and existing accounts.
Key financial highlights include a gross margin of 88% for the fourth quarter and 87% for the full year, indicating strong profitability. Despite a net loss of $12.6 million in the fourth quarter and $40.5 million for the full year, the company has made substantial investments in its commercial operations and increased headcount to support growth. Additionally, Ceribell submitted a 510(k) application for its pediatric Clarity™ algorithm to the FDA, marking a strategic step in expanding its product offerings.
Looking ahead, Ceribell’s management remains optimistic about the company’s growth prospects. For 2025, the company projects revenue to be in the range of $81 million to $85 million, representing a growth of approximately 24% to 30% over the previous year. This outlook reflects Ceribell’s commitment to advancing its mission of improving clinical outcomes for neurology patients and expanding its market presence.